Disposable IV Therapy Products Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Intravenous Medication and Nutrition Utilization

Intravenous administration remains essential for high-acuity medications, as it enables immediate delivery and continuous dose adjustment. It remains critical in intensive care, oncology, and nutritional support, where alternative routes may not meet clinical requirements. Fresenius Kabi reported more than 170 IV drug products in its portfolio and 15 new U.S. IV drug launches during fiscal year 2025. These launches continue to support demand for compatible administration sets and disposable IV therapy products.

Growth in Chronic Disease, Surgery, and Critical Care

Chronic diseases, surgical procedures, and critical care continue to increase the need for IV access across care settings. Australia recorded 12.8 million hospitalizations and 43.6 million outpatient services in 2024-2025.^[1] India’s AB PM-JAY scheme had authorized 11.69 crore hospital admissions across 1,961 procedures by February 2026. Longer treatment cycles, including chemotherapy, dialysis, and IV diuretic therapy, support demand for catheters, connectors, and administration sets.^[2]

Expansion of Home and Ambulatory Infusion Care

Infusion therapy is shifting from hospital outpatient departments to home and ambulatory care settings. In March 2026, the National Home Infusion Association stated that home infusion therapy was evolving across treatment categories and managing increasingly complex care needs.^[3] Home-compatible sets support simple priming and administration by patients or caregivers and may work with elastomeric or wearable pump platforms. Ambulatory surgical centers also drive demand for single-use IV consumables.

Needleless Access and Infection Prevention Requirements

Bloodstream infection prevention is increasing the importance of safety features in IV consumables purchasing decisions. The World Health Organization guides the prevention of infections associated with peripheral and central intravascular catheters and supports needleless access systems for safe catheter care. In March 2025, ICU Medical received FDA 510(k)-cleared labeling claims for its Clave portfolio, citing a statistically significant reduction in bloodstream infection risk compared with non-Clave connectors. These factors strengthen demand for safety-engineered connectors and closed systems.

Pricing Pressure From Tendering and Volume-Based Procurement

Group purchasing organizations and public tenders place persistent pricing pressure on IV consumables. In China, volume-based procurement has extended to medical devices and sets price expectations for standard IV products. Domestic suppliers can often meet these expectations more easily than multinationals with higher cost structures. Commodity administration sets and basic peripheral catheters face the most direct pressure, while manufacturers are investing in antimicrobial coatings, closed systems, and connectivity features to support product differentiation. Longer hospital payment cycles also increase working capital pressure across the disposable IV therapy products market.

Transition Risk From PVC, DEHP, and Other Material Restrictions

European Union Regulation 2023/2482 set July 1, 2030, as the sunset date for DEHP use in medical devices and January 1, 2029, as the latest application date for authorization. Manufacturers of PVC-plasticized IV sets and catheters must accelerate reformulation and requalification plans. Alternative plasticizers require assessment for chemical compatibility, extractables, sterility, product performance, and drug compatibility with polyolefin- or EVA-based alternatives. Companies with large PVC-based portfolios must choose between reformulation, substitution, or withdrawal, increasing costs for producers focused on PVC processing rather than polymer materials development.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Disposable IV Therapy Products Market Segment Analysis

IV catheters and cannulas accounted for 45.67% of the disposable IV therapy products market size in 2025, reflecting the widespread need for peripheral IV access in acute-care settings. In April 2026, BD launched the BD CentroVena One Insertion System following FDA 510(k) clearance and acceptance into the FDA Safer Technologies Program for Medical Devices. The system reduced insertion steps by 30% and simulation insertion time by 50%. BD also received FDA 510(k) clearance for its Insyte IV Catheter, supporting workflow efficiency and insertion safety.

Infusion pumps are forecast to grow at a 7.76% CAGR through 2031, the highest rate among product types. Pump replacement cycles drive recurring demand for compatible administration and extension sets, while needleless connectors and disinfection caps require frequent replacement. In 2025, B. Braun reported that 106 hospitals converted to its Introcan Safety catheter family and that it trained more than 31,000 clinicians. Specialty access sets, anti-siphon extension sets, and flow-regulation accessories are gaining relevance as home and ambulatory therapy protocols become more complex.

Disposable and single-use products held 76.55% of revenue in 2025 and are forecast to grow at an 8.20% CAGR through 2031. This category remains the largest and fastest-growing usability segment as providers move away from reusable products in specialty applications and emerging markets. Infection prevention supports this shift by eliminating cleaning and reprocessing requirements. A 2025 peer-reviewed review highlighted catheter-related infection prevention and the clinical consequences of catheter-related complications.

On July 22, 2026, Nipro began domestic sales of its ORCHID IV line connector in Japan. The connector disconnects safely when tubing is exposed to excessive pulling force, reducing accidental extubation and skin damage in nursing settings with reduced use of physical restraints. Reusable products retain relevance in cost-constrained locations with adequate sterilization infrastructure. However, declining single-use product costs and the focus on consistent infection-control practices continue to strengthen demand for disposable products.

Medication administration represented 34.89% of the disposable IV therapy products market size in 2025, supported by the IV delivery of antibiotics, analgesics, anticoagulants, chemotherapy, and biologics. This application creates sustained demand for administration sets, connectors, and catheters. In April 2025, ICU Medical received FDA 510(k) clearance for its Plum Solo and Plum Duo precision IV pumps. The pumps delivered ±3% accuracy under real-world conditions, including variations in temperature and pump placement.

Fluid replacement and hydration are forecast to grow at a 6.56% CAGR through 2031. Surgical care requires perioperative fluid management, sepsis protocols require rapid fluid resuscitation, and home hydration supports selected patients receiving chemotherapy or recovering from gastrointestinal illness. Parenteral nutrition remains a stable application because it requires specialized multi-lumen access and lipid-compatible sets. Chemotherapy, dialysis and renal care, pain management, and specialty infusion require distinct product specifications and clinical handling practices.

Hospitals held 55.67% of revenue in 2025 due to high inpatient volumes, broad IV applications, and centralized procurement systems. Baxter’s Infusion Therapies and Technologies division reported USD 1,745 million in revenue in the second quarter of 2026. The division includes IV solutions, drug compounding, and administration sets, highlighting the importance of the hospital channel. Specialty clinics and long-term care facilities also generate demand, particularly oncology clinics using protocol-specific chemotherapy sets.

Ambulatory surgical centers are forecast to grow at a 6.97% CAGR through 2031 as selected procedures shift from hospitals. Each procedure requires a new peripheral IV setup and may require arterial lines, central access, or specialized fluid sets. Home healthcare also supports demand for gravity sets, elastomeric pump sets, and portable-compatible catheters. In 2025, Fresenius Kabi introduced software upgrades for the Ivenix smart infusion platform covering cybersecurity, workflow optimization, and electronic medical record connectivity.

Geography Analysis

North America Disposable IV Therapy Products Market

North America held a 40.56% revenue share in 2025, supported by robust acute-care infrastructure, high procedure volumes, and established adoption of safety-oriented IV consumables. On January 14, 2026, Health Canada cleared ICU Medical’s Plum Solo and Plum Duo precision IV pumps, expanding access for Canadian healthcare organizations. The shift toward ambulatory and home-based care is increasing demand for specialized consumables with appropriate usability and pump compatibility.

Europe and APAC Disposable IV Therapy Products Market

Europe remained the second-largest regional market, led by Germany, the United Kingdom, and France. In September 2025, Fresenius Kabi secured a EUR 400 million loan from the European Investment Bank to expand medical product and biosimilar manufacturing capacity. The funding supported administration-set and infusion-system capacity, while the Medical Device Regulation and the DEHP sunset continued to reshape PVC-dependent portfolios. Asia-Pacific is forecast to grow at a 7.77% CAGR through 2031, supported by India’s AB PM-JAY program, which had authorized 11.69 crore admissions across 1,961 procedures by February 2026.

APAC, MEA, South America and Oceania Disposable IV Therapy Products Market

China strengthened standards for single-use gravity-feed infusion sets through T/CAMDI 154-2025, aligning with the GB 8368 framework and ISO 8536-4. BD launched its Nexiva Closed IV Catheter System in Indonesia in December 2025. The Middle East and Africa expanded from a lower base as GCC countries developed tertiary-care facilities, while South America remained divided between larger hospital markets in Brazil and Argentina and price-constrained markets elsewhere. In 2025, Baxter and the Australian Government announced a AUD 40 million joint investment, equivalent to USD 25.8 million, to expand IV fluid manufacturing in Old Toongabbie, Western Sydney.